MORABITO, FORTUNATO
 Distribuzione geografica
Continente #
NA - Nord America 384
EU - Europa 283
AS - Asia 224
AF - Africa 5
Totale 896
Nazione #
US - Stati Uniti d'America 382
IT - Italia 206
CN - Cina 122
SG - Singapore 96
DE - Germania 26
FI - Finlandia 25
AT - Austria 10
NL - Olanda 9
CZ - Repubblica Ceca 2
ET - Etiopia 2
JP - Giappone 2
KR - Corea 2
PA - Panama 2
SC - Seychelles 2
DK - Danimarca 1
ES - Italia 1
FR - Francia 1
GB - Regno Unito 1
LT - Lituania 1
MO - Macao, regione amministrativa speciale della Cina 1
PH - Filippine 1
SN - Senegal 1
Totale 896
Città #
Boardman 138
Florence 127
Singapore 78
Ashburn 63
Shanghai 41
Sesto Fiorentino 23
Noto 22
Washington 19
Helsinki 17
Munich 14
Los Angeles 11
Ogden 11
Guangzhou 10
Lappeenranta 8
Vienna 8
Wuhan 8
Naaldwijk 7
Beijing 5
Milan 5
New York 4
Palmi 3
Addis Ababa 2
Amsterdam 2
Bari 2
Gualdo Tadino 2
Jinhua 2
Naples 2
Nuremberg 2
Rome 2
Seoul 2
Shenzhen 2
Tokyo 2
Turin 2
West Jordan 2
Wuxi 2
Bologna 1
Brooklyn 1
Catania 1
Chicago 1
Cirò Marina 1
Cologne 1
Dakar 1
Dalian 1
Frankfurt am Main 1
Jiaxing 1
Lianyun 1
Macao 1
Madrid 1
Manila 1
Modigliana 1
Nanjing 1
Newark 1
Qingdao 1
Rende 1
San Francisco 1
Santa Barbara 1
Santa Clara 1
Seattle 1
Shijiazhuang 1
Taizhou 1
Tiantai Chengguanzhen 1
Udine 1
Weifang 1
Yiwu 1
Zhongshan 1
Zibo 1
Totale 681
Nome #
Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials 34
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients 32
Dissecting the Biological Relevance and Clinical Impact of lncRNA MIAT in Multiple Myeloma 31
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials 30
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials 30
Elotuzumab in multiple myeloma 30
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study 29
Antitumor Effects of PRIMA-1 and PRIMA-1Met (APR246) in Hematological Malignancies: Still a Mutant P53-Dependent Affair? 28
Validation of the Alternative International Prognostic Score-E (AIPS-E): Analysis of Binet stage A chronic lymphocytic leukemia patients enrolled into the O-CLL1-GISL protocol 27
Efficacy of front-line ibrutinib versus fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: A retrospective multicenter "Real-World" study 27
Teclistamab-cqyv in multiple myeloma 27
Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials 26
Iron chelation therapy 26
Belantamab mafodotin in multiple myeloma 25
TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases 24
Myelodysplastic syndromes with ring sideroblasts 23
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases 23
Lymphocyte Doubling Time As A Key Prognostic Factor To Predict Time To First Treatment In Early-Stage Chronic Lymphocytic Leukemia 23
Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study 23
MiR-146b-5p regulates IL-23 receptor complex expression in chronic lymphocytic leukemia cells 22
The time to first treatment is an independent predictor of overall survival in chronic lymphocytic leukemia 22
Genes selection using deep learning and explainable artificial intelligence for chronic lymphocytic leukemia predicting the need and time to therapy 21
LINC00152 expression in normal and Chronic Lymphocytic Leukemia B cells 21
Heterogeneity of TP53 Mutations and P53 Protein Residual Function in Cancer: Does It Matter? 21
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective real-world experience with 200 cases outside of controlled clinical trials 20
Human pluripotent stem cells identify molecular targets of trisomy 12 in chronic lymphocytic leukemia patients 19
Acalabrutinib in chronic lymphocytic leukemia 19
Mechanisms of Immune Evasion in Multiple Myeloma: Open Questions and Therapeutic Opportunities 16
Spotlight on Melphalan Flufenamide: An Up-and-Coming Therapy for the Treatment of Myeloma 16
Ivosidenib in acute myeloid leukemia 15
Anti-CD38 monoclonal antibodies in multiple myeloma with gain/amplification of chromosome arm 1q: a review of the literature 15
Glasdegib for the treatment of acute myeloid leukemia 14
Isatuximab in multiple myeloma 14
Momelotinib in myelofibrosis 14
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow-up of a multicenter, retrospective real-world experience with 321 cases outside of controlled clinical trials 14
Selinexor in multiple myeloma 12
Transcriptomic Analysis in Multiple Myeloma and Primary Plasma Cell Leukemia with t(11;14) Reveals Different Expression Patterns with Biological Implications in Venetoclax Sensitivity 12
Safe and Effective Administration of Caplacizumab in COVID-19-Associated Thrombotic Thrombocytopenic Purpura 11
Potential of BGB-1417, a BCL2 inhibitor, in hematological malignancies 11
Ibrutinib as first line therapy in chronic lymphocytic leukemia patients over 80 years old: A retrospective real‐life multicenter Italian cohort 11
Myelodysplastic syndromes del(5q): Pathogenesis and its therapeutic implications 10
Safety and efficacy of caplacizumab in a case of thrombotic thrombocytopenic purpura in the postpartum period 10
Zanubrutinib for the treatment of chronic lymphocytic leukemia 10
TP53 Mutations with Low Variant Allele Frequency Predict Short Survival in Chronic Lymphocytic Leukemia 9
Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens 8
Mosunetuzumab for the treatment of follicular lymphoma 8
Investigational CXCR4 inhibitors in early phase development for the treatment of hematological malignancies 7
Tagraxofusp in myeloid malignancies 7
The potential of triplet combination therapies for patients with FLT3-ITD -mutated acute myeloid leukemia 6
Venetoclax in acute myeloid leukemia 6
The role of corticosteroids in the current treatment paradigm for myelofibrosis 5
MicroRNA Profiling as a Predictive Indicator for Time to First Treatment in Chronic Lymphocytic Leukemia: Insights from the O-CLL1 Prospective Study 5
Therapy‐Related Acute Promyelocytic Leukemia: Case Series and Current Insights 3
Totale 952
Categoria #
all - tutte 9.805
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 9.805


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2022/202369 0 0 0 0 0 0 30 4 4 4 21 6
2023/2024599 9 14 121 91 53 90 29 21 20 10 21 120
2024/2025284 56 112 33 72 11 0 0 0 0 0 0 0
Totale 952